600774 Hanshang Group
- 7.98
- -0.34-4.09%
Hanshang Group News
Hanshang Group Co., Ltd. (SHSE:600774) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
The Hanshang Group Co., Ltd. (SHSE:600774) share price has done very well over the last month, posting an excellent gain of 28%. Not all shareholders will be feeling jubilant, since the share price
Hanshang Group (600774.SH): Plans to purchase 100% of Zheng An Industrial's shares and the “operating assets of the Wuhan Living Room Project” by issuing shares, etc.
Gelonghui, May 22丨Hanshang Group (600774.SH) announced that the company intends to purchase 100% of its shares in Zhengan Industrial (Wuhan) Co., Ltd. held by Zhuoer International Business Management Wuhan Partnership (Limited Partnership) and Zhengan Asset (Cayman Islands) Industrial Co., Ltd. by issuing shares and paying cash, to purchase “Wuhan Living Room Project Operating Assets” held by Zhuoercheng Investment and Development Co., Ltd. by issuing shares to no more than 35 specific targets (hereinafter referred to as “this transaction”). The transaction is expected to constitute a significant asset
Is Hanshang Group Co., Ltd.'s (SHSE:600774) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Most readers would already be aware that Hanshang Group's (SHSE:600774) stock increased significantly by 58% over the past three months. We wonder if and what role the company's financials play in t
Gelonghui Announcements Selected | HuaTest Navigation: The actual controller's concerted actions plan to increase the company's shares by 120 million yuan to 200 million yuan; Hanshang Group: Currently not developing stem cell treatment business
[Hot Focus] Hanshang Group (600774.SH): Currently not operating stem cell treatment business Hanshang Group (600774.SH) announced abnormal stock trading fluctuations, and the company is not currently engaged in stem cell treatment business. The company's Wuhan Huake Reproductive Specialist Hospital was awarded the “Hubei Engineering Research Center for Human Stem Cell Preparation and Application and Resource Preservation”. Currently, it is in the early stages of research and development, and no clinical application has been carried out. There have been no major changes in the company's main business, and there have been no major changes in fundamentals. Xinghu Technology (600866.SH): Shareholders Yipin Group and Tie Xiaorong reduced their total holdings
Hanshang Group (600774.SH) announced its 2023 annual results. Net profit of 61.2064 million yuan decreased by 32.24% year on year
According to Zhitong Finance App, Hanshang Group (600774.SH) released its 2023 annual performance report. During the reporting period, the company achieved operating income of 1.39 billion yuan, an increase of 0.19%; net profit attributable to shareholders of listed companies was 61.2064 million yuan, a year-on-year decrease of 32.24%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 376.931 million yuan, a year-on-year decrease of 15.67%; and basic earnings per share were 0.2075 yuan.
Hanshang Group (600774.SH): Received 17.88 million yuan in government subsidies
Gelonghui, April 22丨Hanshang Group (600774.SH) announced that the company and its affiliated enterprises received a total of 17,882,339.82 yuan in government subsidies between August 29, 2023 and the date of publication of this announcement. Among them, the income-related subsidy was RMB 15,902,339.82, accounting for 17.97% of the company's most recent audited net profit attributable to shareholders of the listed company; the asset-related subsidy was RMB 1,980,000.00, accounting for 0.12% of the company's most recent audited net assets.
Hanshang Group (600774.SH): No participation or use of AI
Gelonghui, March 27丨Hanshang Group (600774.SH) said on an interactive platform that the company is currently not participating in or using AI.
Hanshang Group (600774.SH): Currently does not produce or sell atropine related pharmaceutical products
Gelonghui, March 27丨Hanshang Group (600774.SH) said on an interactive platform that its holding subsidiary Chongqing Dikang Changjiang Pharmaceutical Co., Ltd. holds atropine-related drug approvals (Sinopharm H50020864, Sinopharm H50020865, Sinopharm H50020866), but currently does not produce or sell atropine related pharmaceutical products.
Hanshang Group (600774.SH): Some directors, supervisors and managers plan to increase their holdings of the company by 5 million yuan to 7 million yuan
Gelonghui, Feb. 7: Hanshang Group (600774.SH) announced that some of the company's directors, supervisors and managers plan to increase their holdings of the company's shares through centralized bidding in the Shanghai Stock Exchange system for a period of six months from February 8, 2024. There is no set price range for this increase. The total amount of increase in holdings will not be less than RMB 5 million, not more than RMB 7 million.
Earnings Working Against Hanshang Group Co., Ltd.'s (SHSE:600774) Share Price Following 26% Dive
The Hanshang Group Co., Ltd. (SHSE:600774) share price has fared very poorly over the last month, falling by a substantial 26%. The drop over the last 30 days has capped off a tough year for shareh
Should Weakness in Hanshang Group Co., Ltd.'s (SHSE:600774) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
It is hard to get excited after looking at Hanshang Group's (SHSE:600774) recent performance, when its stock has declined 13% over the past week. But if you pay close attention, you might find that
Meilleure Health Sells 661,408 Shares of Hanshang Group
Meilleure Health International Industry Group (HKG:2327) said it sold 661,408 shares of Hanshang Group (SHA: 600774) in the secondary market in October 2023, for roughly HK$6.7 million. Proceeds will
Merry Health International (02327) further sells 661,400 shares of Han Shang (600774.SH) shares
Merry Health International (02327) announced that from October 20 to 31, 2023, the Group will advance...
Hanshang Group (600774.SH)'s net profit for the third quarter was 206.685 million yuan, a year-on-year decrease of 10.06%
On October 27, Gelonghui Group (600774.SH) announced its report for the third quarter of 2023. In July-September 2023, operating income was 315 million yuan, a year-on-year decrease of 2.46%; net profit attributable to shareholders of listed companies was 206.685 million yuan, a year-on-year decrease of 10.06%; and net profit attributable to shareholders of listed companies after deducting non-recurring profits and losses - 9104,000 yuan.
Hanshang Group (600774.SH): The product has successfully landed in more than 10,000 public and private hospitals in China
Glonghui September 5 | At the September 5 performance briefing, Hanshang Group (600774.SH) said that in terms of sales, the company attaches great importance to sales achievement capabilities, carefully trains marketers, and has formed a sales elite team of more than 400 people, spread across 31 provinces, cities, and autonomous regions across the country, reaching various sales channels such as hospitals, retail pharmacies, primary medical institutions, clinics, and e-commerce platforms. By providing professional services, marketers accurately convey the company's product knowledge and advantages to the market. The products have successfully landed in more than 10,000 public and private hospitals in China; at the same time, they have accelerated the retail side and the channel layout of the three terminals, which has now been repeated
Hanshang Group (600774.SH): The transfer of drug approvals from Oriental Pharmaceutical to Dikang Traditional Chinese Medicine has basically been completed
Glonghui September 5 | Hanshang Group (600774.SH) said at the September 5 performance briefing that the company established Chongqing Dikang Traditional Chinese Medicine Pharmaceutical Co., Ltd. as the company's traditional Chinese medicine development platform, undertook 92 pharmaceutical product approvals and related production assets from Dongfang Pharmaceutical, and made every effort to promote the resumption of work and production. At present, Dikang Traditional Chinese Medicine has obtained a pharmaceutical production license, and the transfer of the original Oriental Pharmaceutical drug approval to Dikang Traditional Chinese Medicine has also been basically completed. In the future, the company will use Dikang Traditional Chinese Medicine as a platform for the development of traditional Chinese medicine, rely on the company's superior sales resources, enrich the diversity of the product portfolio, and create unique product competitiveness and brand value to help the public
Hanshang Group (600774.SH): Plans to further expand the scale of self-hosted exhibitions in the future to increase the gross profit margin of the exhibition business
Glonghui September 5 | Hanshang Group (600774.SH) said at the September 5 performance briefing that in the first half of 2023, the company's exhibition business division's revenue was 33.152,300 yuan, an increase of 83.40% over the previous year. At a time when the market economy is fully recovering, the exhibition, as an important communication platform for all walks of life in the industrial chain, ushered in a perfect opportunity for the industry to restore confidence in development. The company is an exhibition operator and exhibition supporting service provider. It mainly acts as an organizer or organizer of exhibition events. It provides customers with exhibition supporting services such as exhibition engineering services and management consulting. By collecting exhibition hall usage fees and facilities
Hanshang Group (600774.SH) announced its first half results, with net profit of 48.2084 million yuan, an increase of 13.06% over the previous year
Hanshang Group (600774.SH) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
Hanshang Group (600774.SH) Discloses Major Asset Restructuring Plan and Resumption of Stock Trading
Hanshang Group (600774.SH) announced that the company intends to open up with Zhuoer International Business Management by issuing shares...
Hanshang Group (600774.SH): Received a total of 16.7581 million yuan in government subsidies
GLONGHUI, August 14丨Hanshang Group (600774.SH) announced that during the period from December 29, 2022 to the date of publication of this announcement, the company and affiliated enterprises received a total of 16.7581 million yuan in government subsidies, accounting for 18.94% of the company's latest audited net profit attributable to shareholders of listed companies.
Analysis
Price Target
No Data
